ReviewStem cell research & therapy2025
MiRNA delivery systems in cancer stem cell therapy: exosomes versus chitosan nanoparticles.
Review in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Therapeutic Potential of Stem Cell Therapy for Doxorubicin-Induced Cardiotoxicity: A Narrative Review.Health science reports · 2026Article
- From Environmental Risk to Cancer Stemness: Epigenetic Regulation in Oral Squamous Cell Carcinoma.Pharmaceuticals (Basel, Switzerland) · 2026Review
- miRNAs-neutrophil axis: novel insights into acute lung injury and chronic inflammatory lung diseases.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cancer stem cells (CSCs), refer to small subpopulations of cancer cells within a tumor mass representing stemness properties such as high self-renewal capacities, differentiation potential, metastasis, therapy resistance, and tumor recurrence. These cells are the main reason for cancer treatment failure and the inefficacy of traditional therapeutic approaches. Accordingly, focusing on molecular mechanisms underlying CSCs and targeting them is the new era in the field of cancer. MicroRNAs (miRNAs) are a class of noncoding RNAs that play an important role in the formation and progression of CSCs by regulating the expression of stemness markers and critical genes implicated in CSC signaling pathways. Many studies have reported that some miRNAs have aberrant expression in CSCs. Dysregulated miRNAs can be a promising candidate as a therapeutic target for eradicating CSCs, but their delivery into CSCs could be challenging. Notably, numerous studies have shown that natural nanoparticles such as exosomes and chitosan nanoparticles (CSNPs) are among the most extensively exploited nano vehicles for miRNA delivery. In the present review, we focus specifically on CSNPs- and exosome-based CSC-targeted therapies and provide the key advantages and shortcomings of these systems as miRNA delivery systems for targeting CSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.